Amylyx Pharmaceuticals Inc.

Home
United States
Cambridge, MA
Amylyx Pharmaceuticals Inc.

Ushering in a new era for treating diseases with high unmet needs

03/31/2026

ALS affects as many as 30,000 adults in the U.S. and 3,000 in Canada. The most common form of the disease is sporadic ALS, with more than 90% of people with ALS showing no clear family history. Learn more about ALS on our website at https://bit.ly/4sIuXtH

03/26/2026

Maria was told she wouldn’t survive another year without bariatric surgery. The procedure saved her life, but a new challenge emerged: post-bariatric hypoglycemia ( ).

At Amylyx, we’re committed to listening to and learning from those living with PBH. In this clip, Maria and her daughter Kelly reflect on the highs and lows of her journey and the hope for treatment. Watch Maria’s full story here: https://bit.ly/4c8TlPe

03/24/2026

We’re pleased to announce the completion of enrollment in our pivotal Phase 3 LUCIDITY trial in post-bariatric hypoglycemia (PBH).

Thank you to the LUCIDITY trial sites and participants for their study contributions and commitment to driving innovation!

We look forward to topline data from the trial, which is expected in Q3 2026. See today’s press release for more information: https://bit.ly/4btlG2z

03/20/2026

Wolfram syndrome is a rare genetic disorder that affects multiple organs and systems over time.

Most people with Wolfram syndrome have mutations in the WFS1 gene, which encodes wolframin, a protein essential for maintaining endoplasmic reticulum (ER) homeostasis and normal cellular function.

When wolframin is impaired, cells experience chronic ER stress and mitochondrial dysfunction. Learn more about Wolfram syndrome on our website at https://bit.ly/3NQQ3H5

03/09/2026

This week, is at Muscular Dystrophy Association's Clinical and Scientific Conference, where we’re presenting an update on our Phase 1 LUMINA trial in . More details below.

02/27/2026

Ahead of tomorrow, Amylyx honors the resilience of those living with rare diseases and the communities that stand beside them. At our recent Anchor Week, we gathered for a Rare Night Out to recognize our shared purpose and participated in Rare Disease Trivia to promote awareness and connection.

02/24/2026

Happy Amylyx Anniversary to Jim Frates, Dan Sitte, Jenny Tavares, and Eric Cooksey! At this month’s Anchor Week, we celebrated the many contributions they’ve made the past 5 years and thanked them for their unwavering commitment to developing novel therapies for communities with high unmet needs.

02/19/2026

We were honored to host Cindy and her husband Ray at our recent Anchor Week. They shared with us the partnership, determination, and hope that have been critical throughout Cindy's journey with post-bariatric hypoglycemia (PBH).

The communities we collaborate with drive us forward, and Cindy and Ray brought our work to life in such a powerful way. Thank you for speaking with !

02/17/2026

Post-bariatric hypoglycemia (PBH) is thought to be caused by changes in hormonal and glycemic patterns, including an excessive glucagon-like peptide-1 (GLP-1) response, leading to repeated episodes of low blood sugar (also know as hypoglycemia) that impair quality of life.

Over time, repeated episodes of hypoglycemia can lead to hypoglycemia unawareness, a condition where the body does not produce the typical early warning signs of hypoglycemia until blood sugar levels drop dangerously low. Learn more about PBH on our website at https://bit.ly/4tCBxTD

02/12/2026

What does it mean to be Rooted in Connection?

Amylyx values the connections between our company and the communities we serve, between questions and solutions, and between insights and actions. We see a path between where we are and where we need to be. Our work, our motivation, and the core values that guide us are deeply interwoven.

Learn more about our company: https://bit.ly/4qsj2OF

02/11/2026

Last week, gathered at headquarters for Anchor Week, a special time for collaboration and connection across our hybrid-remote team and with guests from the broader community. Check out some of the highlights below.

02/06/2026

Raquel’s path to a diagnosis of started at 4 years old when she was diagnosed with diabetes. She started losing her vision at 5 years old. In honor of upcoming , hear her story on this rare condition that affects approximately 3,000 people in the U.S. at https://bit.ly/3Zmju65

Address

55 Cambridge Parkway, Suite 6W
Cambridge, MA
02142

Website

https://www.amylyx.com/, https://www.amylyx.com/social-media-guidelines, https://www.amylyx.com/privacy-notice

Alerts

Be the first to know and let us send you an email when Amylyx Pharmaceuticals Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Amylyx Pharmaceuticals Inc.:

Want your practice to be the top-listed Clinic in Cambridge?